Abstracts Archive - Page 1227 of 2425 - ACR Meeting Abstracts

Abstract Number: 322 • 2017 ACR/ARHP Annual Meeting
Safety of Denosumab in a Monocentric Cohort of Kidney Transplant Recipients
Sonia Doddoli, Pierre Lafforgue and Thao Pham, Rheumatology, APHM, Aix Marseille Univ, Marseille, France
Background/Purpose: Safety of denosumab, a fully human monoclonal antibody against RANKL developed for osteoporosis and prevention of fracture remains unclear in kidney transplanted patients. A…
Abstract Number: 323 • 2017 ACR/ARHP Annual Meeting
Evaluation of Invasive Oral Procedures and Events in Women with Postmenopausal Osteoporosis Treated for up to 10 Years with Denosumab: Results from a Phase 3 Open-Label Extension Study
Nelson B. Watts¹, John T. Grbic², Neil Binkley³, Peter W. Butler⁴, Xiang Yin⁴, Antoniette Tierney⁴, Rachel B. Wagman⁴ and Michael McClung⁵, ¹Mercy Health, Cincinnati, OH, ²Columbia University, New York, NY, ³University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Oregon Osteoporosis Center, Portland, OR
Background/Purpose: Antiresorptive therapy use is associated with osteonecrosis of the jaw (ONJ), an infrequent but serious adverse event. Positively adjudicated ONJ in the denosumab (DMAb)…
Abstract Number: 324 • 2017 ACR/ARHP Annual Meeting
The Predictors of the Efficacy of Denosumab, a Monoclonal Antibody to RANK Ligand, on Osteoporosis in Rheumatoid Arthritis Patients from Japanese Multicenter Study
Kyosuke Hattori¹, Yuji Hirano¹, Yasuhide Kanayama², Nobunori Takahashi³, Naoki Ishiguro³ and Toshihisa Kojima³, ¹Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ²Orthopaedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Although early intensive treatment has improved medication of rheumatoid arthritis (RA), treatment for osteoporosis (OP) in RA patient will be more important. Here, we…
Abstract Number: 325 • 2017 ACR/ARHP Annual Meeting
Zoledronic Acid Did Not Impaired Renal Function in Patients with Osteoporosis
Ying-Chou Chen Sr., Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung County, Taiwan
Background/Purpose: Bisphosphonates are recommended for patients with osteoporosis, however concerns have been raised with regards to their effect on kidney function. The aim of this…
Abstract Number: 326 • 2017 ACR/ARHP Annual Meeting
Osteoporosis and Vertebral Fractures Are Associated with Disease Activity, Low Vitamin D Levels and Spinal Radiographic Damage in Patients with Axial Spondyloarthritis
Cintia Romera-López¹, Cristina Fernández-Carballido², Miguel Ángel García-Moreno³ and Teresa Pedraz⁴, ¹Rheumatology, Hospital Universitario del Vinalopó, Elche, Spain, ²Hospital General Universitario de Elda, Elda, Spain, ³Hosppital Universitario de Elda, Elda, Spain, ⁴Hospital Universitario de Elda, Elda, Spain
Background/Purpose: Osteoporosis and vertebral fractures are comorbidities of Axial Spondyloarthritis (axSpA). We evaluated the relationship between disease activity and radiographic damage and bone mineral density…
Abstract Number: 327 • 2017 ACR/ARHP Annual Meeting
Association of Anti-Cyclic Citrullinated Peptide Seropositivity and Lean Mass Index with Low Bone Mineral Density in Patients with Rheumatoid Arthritis
Katherine D. Wysham¹, Dolores M. Shoback², Kashif Jafri¹, Sarah L. Patterson³, Gabriela Schmajuk⁴, John B. Imboden Jr.⁵ and Patricia P. Katz⁵, ¹University of California, San Francisco, San Francisco, CA, ²Medicine, San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, ³Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, ⁵Medicine, University of California, San Francisco, San Francisco, CA
Background/Purpose: Osteoporotic fractures are associated with high morbidity and mortality. Persons with rheumatoid arthritis (RA) have twice the risk of osteoporosis-related fracture than age-matched…
Abstract Number: 328 • 2017 ACR/ARHP Annual Meeting
Secular Trends in the Risk of Fragility Fracture Among Patients with Rheumatoid Arthritis: A General Population-Based Study
Sarah Keller¹, Marcy B. Bolster², Amar Oza³, Sharan K. Rai⁴, Leo Lu³, Yuqing Zhang⁵ and Hyon K. Choi⁴, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The risk of osteoporotic (OP) fracture among patients with rheumatoid arthritis (RA) is higher than that of the general population. The worldwide incidence of…
Abstract Number: 329 • 2017 ACR/ARHP Annual Meeting
Factors Associated with Worsening Serum Vitamin D Deficiencies in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study
Masanori Nakayama¹, Takefumi Furuya¹, Eisuke Inoue², Eiichi Tanaka¹, Katsunori Ikari¹, Ayako Nakajima¹, Atsuo Taniguchi¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: In 2011, we evaluated serum vitamin D levels in Japanese patients with rheumatoid arthritis (RA) and reported the prevalence of, and factors associated with,…
Abstract Number: 330 • 2017 ACR/ARHP Annual Meeting
Change in Bone Mineral Density in Patients with Rheumatoid Arthritis: Minimal 10-Year Follow-up
Hiraku Motomura, Isao Matsushita, Toshihito Hiraiwa and Tomoatsu Kimura, Department of Orthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan
Background/Purpose: To investigate the long-term change in bone mineral density (BMD) in patients with rheumatoid arthritis (RA). Methods: In a longitudinal study of 40 patients…
Abstract Number: 331 • 2017 ACR/ARHP Annual Meeting
Case Series: Comparison of Repository Corticotropin Injection (H.P. Acthar Gel) Versus Glucocorticoids on Bone Density in SLE Patients
Anny T. Wu¹ and Joshua June², ¹Rheumatology, Franciscan Alliance, Munster, IN, ²3394 E Jolly Rd Ste C, Great Lakes Center of Rheumatology, Lansing, MI
Background/Purpose: Repository Corticotropin Injection (RCI) is an adrenocorticotropin hormone in 16% gelatin with a prolonged release after intramuscular (IM) or subcutaneous injection. Adverse effects of…
Abstract Number: 332 • 2017 ACR/ARHP Annual Meeting
Serum 25-Hydroxyvitamin D, Acute Phase Reactants and Disease Activity in Rheumatologic Diseases
María Lorena Brance^1,2, Lucas Ricardo Brun³, Maria Larroude⁴, Mónica Patricia Sacnun⁵, Carolina Aeschlimann⁵, Guillermo Berbotto⁶, Mariano Palatnik¹, Ignacio Chavero¹ and Ariel Sánchez⁷, ¹Centro de Reumatología, Rosario, Argentina, ²School of Medicine. Rosario National University., Bone Biology Laboratory, Rosario, Argentina, ³School of Medicine. Rosario National University, Bone Biology Laboratory, Rosario, Argentina, ⁴Centro de Diagnostico Rossi, Buenos Aires, Argentina, ⁵Hospital Provincial, Rosario, Argentina, ⁶Sanatorio Británico, Rosario, Argentina, ⁷Centro de Endrocrinología., Rosario, Argentina
Background/Purpose: Previous evidence indicates an association between vitamin D deficiency and autoimmune diseases. The aim of this study was to evaluate serum 25-hydroxyvitamin D (25OHD),…
Abstract Number: 333 • 2017 ACR/ARHP Annual Meeting
Atypical Femoral Fracture in Patients of a Rheumatology Service: Clinical, Radiographic and Bone Histomorphometric Data
Mariana O Perez¹, Diogo S Domiciano¹, Vanda Jorgetti² and Rosa M R Pereira¹, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, ²Nephrology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Atypical femoral fractures (AFF) are low energy femoral fractures with a specific radiographic pattern and subtrochanteric / diaphyseal localization that have been related to…
Abstract Number: 334 • 2017 ACR/ARHP Annual Meeting
Comparison of Outcomes in Osteoporosis in Patients on Denosumab between Standard and Non-Standard Dosing Intervals
Nouman A. Syed, Mohammed Wiqar, Douglas Einstadter and Marina N. Magrey, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Denosumab (Dmab) is an antiresorptive agent with an approximate half-life of 26 days and according to the prescribing information the recommended dose is 60…
Abstract Number: 335 • 2017 ACR/ARHP Annual Meeting
Psoriatic Arthritis Patients Who Attain a Very Low Disease Activity State Have a Minimal Impact of the Disease on Their Lives
Rubén Queiro¹, Juan D. Cañete², Carlos Alberto Montilla-Morales³, Miguel A. Abad⁴, Susana Gomez Castro⁵ and Ana Cabez⁵, ¹Rheumatology Department. Hospital Universitario Central de Asturias, Oviedo, Spain, ²Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ³Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ⁴Rheumatology, HU. Virgen del Puerto., Plasencia, Spain, ⁵Pfizer, Madrid, Spain
Background/Purpose: The target of treatment in psoriatic arthritis (PsA) should be remission or inactive disease. A potential definition that would fit with the Treat-to-Target Recommendations…
Abstract Number: 336 • 2017 ACR/ARHP Annual Meeting
Patient–Reported Barriers to Achieving Rheumatoid Arthritis Disease Control
Maria I. Danila¹, Eric M. Ruderman², Leslie R Harrold³, Joshua A. Melnick¹, Ronan O'Beirne¹, Monika M. Safford⁴, Joel Kremer⁵ and Jeffrey R. Curtis⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³University of Massachusetts Medical School, Worcester, MA, ⁴Weill Cornell Medical College, New York, NY, ⁵Corrona, LLC, Southborough, MA, ⁶Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Many patients with RA do not achieve guideline-recommended treat-to-target (T2T) goals in clinical practice. There is a paucity of data regarding the challenges that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].